Pulse Biosciences, Inc., a development-stage medical device company, has been making significant strides in the Health Care sector, particularly within the Health Care Equipment & Supplies industry. Based in Burlingame, United States, Pulse Biosciences is dedicated to revolutionizing medicine through its innovative technology. The company’s approach leverages nanosecond pulsed electric fields to induce cell signaling and activate cellular pathways in tissue, offering a non-invasive, pain-free, and accessible method for tissue healing and regeneration.
As of November 3, 2025, Pulse Biosciences’ stock closed at $16.06 on the Nasdaq, reflecting a market capitalization of approximately $1.13 billion. Despite the challenges often faced by development-stage companies, Pulse Biosciences has maintained a presence in the market, with its stock price fluctuating between a 52-week high of $25 on February 4, 2025, and a 52-week low of $13.766 on April 3, 2025. The company’s price-to-earnings ratio stands at -15.66, indicative of its current stage of development and the speculative nature of its future earnings potential.
Since its Initial Public Offering (IPO) on May 18, 2016, Pulse Biosciences has focused on advancing its proprietary technology. The company’s mission is to transform the landscape of medical treatments by providing solutions that are both effective and patient-friendly. By harnessing the power of nanosecond pulsed electric fields, Pulse Biosciences aims to activate cellular pathways without the need for drugs or invasive procedures, positioning itself as a leader in the field of regenerative medicine.
The company’s innovative approach has garnered attention within the medical community and among investors alike. As Pulse Biosciences continues to develop its technology, it remains committed to its mission of improving patient outcomes through cutting-edge, non-invasive treatments. For those interested in learning more about Pulse Biosciences’ offerings and achievements, further information is available on their website, www.pulsebiosciences.com , or by trading their stocks on the Nasdaq.
In summary, Pulse Biosciences, Inc. is at the forefront of a new era in medical technology, with its focus on non-invasive, drug-free solutions for tissue healing and regeneration. As the company progresses through its development stages, it continues to attract interest from both the healthcare sector and the investment community, promising a future where medical treatments are more accessible and less burdensome for patients worldwide.
